BIOLASE Files Patent Infringement Lawsuit Against European Competitor
25 April 2012 - 11:00PM
Marketwired
BIOLASE Technology, Inc. (NASDAQ: BLTI), the World's leading dental
laser manufacturer and distributor, today announced that it had
filed a lawsuit in the Dusseldorf Patent Litigation Court asserting
that one of its European competitors is infringing on BIOLASE
European Patent EP 1 560 470, which relates to the output of
optical energy of lasers. The lawsuit, filed on April 13, 2012,
seeks both cash damages and injunctive relief from the courts. The
lawsuit was filed after failed attempts were made to create an
amicable business arrangement between the two companies.
Federico Pignatelli, Chairman and CEO, said, "BIOLASE is
committed to asserting its rights in its extensive patent portfolio
in the U.S. and internationally. With more than 280 U.S. and
international patents and patents pending, the Company has invested
heavily in its intellectual property portfolio for laser dentistry
and other medical fields. We will not tolerate what we believe to
be infringement of our patents, and we will be very aggressive in
protecting our rights."
About BIOLASE Technology, Inc. BIOLASE
Technology, Inc., the World's leading Dental Laser Company, is a
medical technology company that develops, manufactures and markets
dental lasers and also distributes and markets dental imaging
equipment, products that are focused on technologies that advance
the practice of dentistry and medicine. The Company's laser
products incorporate 285 patented and patent pending technologies
designed to provide clinically superior performance with less pain
and faster recovery times. Its imaging products provide
cutting-edge technology at competitive prices to deliver the best
results for dentists and patients. BIOLASE's principal products are
dental laser systems that perform a broad range of dental
procedures, including cosmetic and complex surgical applications,
and a full line of dental imaging equipment. BIOLASE has sold more
than 19,000 lasers among 16,000 customers. Other products under
development address ophthalmology and other medical and consumer
markets.
For updates and information on laser and Waterlase dentistry,
find BIOLASE at http://www.biolase.com, Twitter at
http://twitter.com/GoWaterlase, and YouTube at
http://www.youtube.com/user/Rossca08.
This press release may contain forward-looking statements within
the meaning of safe harbor provided by the Securities Reform Act of
1995 that are based on the current expectations and estimates by
BIOLASE management. These forward-looking statements can be
identified through the use of words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates,"
"may," "will," and variations of these words or similar
expressions. Forward-looking statements are based on management's
current, preliminary expectations and are subject to risks,
uncertainties and other factors which may cause the Company's
actual results to differ materially from the statements contained
herein, and are described in the Company's reports it files with
the Securities and Exchange Commission, including its annual and
quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change,
and BIOLASE undertakes no obligation to update such statements.
For further information, please contact: Jill Bertotti Allen
& Caron +1-949-474-4300
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From May 2024 to Jun 2024
Biolase (NASDAQ:BLTI)
Historical Stock Chart
From Jun 2023 to Jun 2024